Worldwide, iron deficiency anemia (IDA) is the most common nutritional deficiency,
and its management remains a challenge in many cases.(OIT)Oral iron therapy, in appropriate
doses and for a sufficient duration, is an effective first-line strategy
for most patients.
But some patients do not experiencean optimal response to(OIT).The need is still
current and clinically relevant for predictors of response to OIT. Hepcidin-25, a major regulator
of iron metabolism, may be use as a reliable guide for the use of iron and be one of
them.112 patientswith IDA were enrolled in this follow up clinical trial, Selected from two
university, hospitals in Damascus between JUNE2015 and JUNE2016. For patients who
met the inclusion criteria, Baseline CBC, iron studies, and serum hepcidin-25 were measured,
and then they received a 14-day course of oral iron (ferrous gluconate 325mg/ 3 times
daily). Patients who achieved <1g/dl increase in Hb in 14 days were categorized as “nonresponders”.
Screening hepcidin levels were (40.18± 86.35) versus (6.37±10.37)(p=
0.041(innonresponders versus responders to oral iron trial. HepcidinCutoff of >14.3 ng/ml,
showed sensitivity of 40%,specificity of 90.2%, andpositive predictive value of 60% andnegative
predictive value of 80% for predicting nonresponsiveness to oral iron.We conclude
that serum hepcidin25predicts poorly nonresponsivenesstooral iron therapy in IDA
patients, but it is superior to ferritin and TSAT for this purpose.
Hepcidin-25 is a peptide hormone plays an important role in
regulating the systematic iron homeostasis. This paper was
conducted to study the correlations of Hepcidin with some iron
status markers and red cell indices among patients with iron
def
iciency anemia (IDA) and healthy controls in Damascus. Our
study comprised 20 IDA patients (Hb≤11 g/dl for men and
women,Tsat≤20% and ferritin <30 ng/dl) and 10 healthy non
IDA controls. Complete hemogram was performed, iron status
markers (serum iron, total iron binding capacity and ferritin)
were measured and transferrin saturation was calculated .
In this prospective study done in Syria from mars 2014 to
February 2015, Mean serum hemoglobin ,serum hematocrit,
serum ferritin, and the ratio of serum iron to total iron-binding
capacity were investigated in 100 children aged ( 2-11) years.
The
study aimed at assessing the extention of anemia in
giardiasis intestinalis in Syrians children.
we delivered 8,000 IU epoetin three times per week to 30 anemic cancer patients for two months.we measured serum erythropoietin level before the initiation of the treatment.Hemoglobin concentration and other hematological parameters were measured dur
ing the treatment. 53% of patients responded to the treatment within 8 weeks. 71% of patients with serum erythropoietin < 100 U/L responded, whereas 27% with values > 100 U/L did.80% of patients with hematological malignancies responded, whereas 39% of patients with solid tumors did .Reticulocyte increment after two weeks in responder patients was higher than non responders.response rate was higher in patients with Hb increment > 0.5 g/dL after 2 weeks ( 83% versus 31% ), and in those with Hb increment > 1 g/dL after 4 weeks ( 93% versus 14% ). response to erythropoietin can be predicted by pretreatment serum erythropoietin level together with early changes in other hematological parameters.
This study aims to show the effectiveness of hydroxyl urea in the treatment of
severe forms of sickle-cell anemia.
The study included 30 patients from patients with sickle cell anemia and who
reviewed the Blood clinics in AL- Assad University Hosp
ital .
We had studied patients treated with hydroxy urea for at least 6 months, where it was
compared to blood and clinical variables before and after hydroxy urea treatment.
The results showed an improvement in blood and clinical manifestations , and it was
noted a significant increase in the level of fetal hemoglobin, and a decrease in the level of
hemoglobin and sickle cell after hydroxy urea treatment.
hydroxy urea treatment also led to a clear increase in the level of total hemoglobin,
and a decrease in the value of total bilirubin.
Decrease in the number of the pain episodes that needed hospitalization, and the
number of times of blood transfusion after treatment, too.
This study evaluates the maternal immunity to chicken anemia virus in broiler chicks.
Two groups, of only one day old chicks, have been breeding .
The first group was obtained from a vaccinated breeder flock against chicken anemia virus .The s
econd one was obtained from unvaccinated breeder flock against the same disease.
Blood samples were collected from the chicks every five days starting from the first day of their birth.
The test was performed enzyme –linked immunoassay (ELISA) to measure antibody titer for chicken anemia virus in these birds.
The research results have shown that the average antibody levels for the first group was (3344) for the one day old chicks while (4144) for the second group.
The results have also shown that there was a decrease in the average antibody levels during 15 days.
This research has proved prevalence of disease in unvaccinated flock
The majority of patients with SCD receive transfusions at some point in their
life. Transfusion can be simple transfusion or exchange transfusions which offer better control of blood
volume and viscosity. Such transfusions are most readily accompli
shed via automated red cell exchange.
Evaluate the results of our experience in applying the technique of selective cell separation by continuous
flow (Cytapheresis) for automated red cell exchange for patients with sickle cell anemia to reduce the level
of hemoglobin S (HbS) in certain cases, especially in preparation for major surgery.
